Morphologic, Metabolic and Functional Prostate Imaging

前列腺形态、代谢和功能成像

基本信息

批准号：
7291676
负责人：
Daniel B Vigneron
金额：
$ 80.53万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-09-27 至 2011-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7291676
关键词：
Address Affect Algorithms Applied Research Base Sequence Benign Bioenergetics Biomedical Engineering Brain Cancer Patient Citrate Citrates Clinical Clinical Trials Collaborations Computer software Data Data Analyses Data Quality Development Diagnostic Diffusion Diffusion Magnetic Resonance Imaging Distant Metastasis Engineering Ferumoxtran-10 Future Gland Goals Histopathology Human Image Imaging Techniques Individual Industry Industry Collaborators Injection of therapeutic agent Laboratories Lead Lymph Node Involvement Magnetic Resonance Imaging Magnetic Resonance Spectroscopy Malignant Neoplasms Malignant neoplasm of prostate Medical Metabolic Metabolism Methodology Methods Metric Modality Monitor Monitoring Clinical Trials Morphologic artifacts Multi-Institutional Clinical Trial Neoplasm Metastasis Nuclear Patients Performance Perfusion Phase Phospholipid Metabolism Phosphorus Physiologic pulse Predisposition Procedures Prostate Prostatic Tissue Publications Pulse taking Range Reading Relaxation Research Research Personnel Resolution Sampling Scheme Scientist Spectrum Analysis Speed System Techniques Testing Time Tissues Translating Translations United States Food and Drug Administration Weight Work base bioimaging cancer imaging design experience human study improved instrument interest iron oxide lymph nodes method development novel performance tests programs reconstruction research clinical testing response spectroscopic imaging technique development tool uptake

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer is extremely common and demonstrates a tremendous range of biologic aggressiveness and varying responses to therapy. Current diagnostic tools are limited in their ability to detect and characterize prostate cancer within the gland, as well as for local and distant metastases. Accurate radiological assessment remains a major problem in treating individual prostate cancer patients and for monitoring clinical trials of emerging therapies. Recently, new MR metabolic, perfusion and diffusion MRI techniques have been investigated to address this pressing clinical need. These studies have, however, been limited by the performance of conventional 1.5 Tesla MR scanners and non-optimal techniques for prostate cancer imaging. The goal of this Bioengineering Research Partnership (BRP) is to develop, test and translate into the clinical setting new 3 Tesla magnetic resonance imaging methods that are aimed ultimately to improve radiological monitoring of prostate cancer patients. The goal is to develop new MR imaging techniques to improve the noninvasive assessment of prostate cancer presence, extent, metabolism, perfusion, and lymph node involvement. Preliminary results have shown dramatic improvements are feasible with the new techniques which may represent major advances in prostate cancer imaging. Following the technique development and optimization in initial patient studies, quantitative performance testing of the new prostate MR imaging methods will be conducted. The goal is to determine the improvements over current techniques and to obtain the initial preliminary data and experience required for the design of future clinical trials of the proposed methods. This partnership will combine the efforts of MR imaging scientists from UCSF (Drs. Vigneron, Kurhanewicz, Nelson and Henry), and Stanford (Drs. Pauly, Cunningham) with industry collaborators from two companies, GE Medical Systems and Cytogen Corporation, that have major interests in prostate cancer imaging. The groups in this partnership have extensive bioengineering experience in the development of biomedical imaging techniques in general and specifically in prostate cancer MR imaging. The industry partners will assist in the technical developments and are required for the translation of the new imaging techniques into commercially available tools that can be widely disseminated to allow their use in research and ultimately clinical investigations world-wide.

描述（由申请人提供）：前列腺癌极为常见，并表现出巨大的生物侵袭性和对治疗的不同反应。目前的诊断工具检测和表征腺体内前列腺癌以及局部和远处转移的能力有限。准确的放射学评估仍然是治疗个体前列腺癌患者和监测新兴疗法的临床试验的主要问题。最近，人们对新的 MR 代谢、灌注和扩散 MRI 技术进行了研究，以解决这一紧迫的临床需求。然而，这些研究受到传统 1.5 特斯拉 MR 扫描仪性能和前列腺癌成像非最佳技术的限制。该生物工程研究合作伙伴关系 (BRP) 的目标是开发、测试新的 3 特斯拉磁共振成像方法并将其转化为临床环境，最终旨在改善前列腺癌患者的放射监测。目标是开发新的磁共振成像技术，以改善对前列腺癌的存在、范围、代谢、灌注和淋巴结受累的无创评估。初步结果表明，新技术的显着改进是可行的，这可能代表了前列腺癌成像的重大进步。在初始患者研究的技术开发和优化之后，将对新的前列腺 MR 成像方法进行定量性能测试。目标是确定对当前技术的改进，并获得设计所提出方法的未来临床试验所需的初始初步数据和经验。此次合作将把加州大学旧金山分校（Vigneron、Kurhanewicz、Nelson 和 Henry 博士）和斯坦福大学（Pauly、Cunningham 博士）的 MR 成像科学家的努力与来自 GE 医疗系统和 Cytogen Corporation 两家公司的行业合作者的努力结合起来，这两家公司在对前列腺癌成像感兴趣。该合作伙伴关系中的团队在开发生物医学成像技术（特别是前列腺癌 MR 成像）方面拥有丰富的生物工程经验。行业合作伙伴将协助技术开发，并需要将新的成像技术转化为可广泛传播的商用工具，以便在全球范围内用于研究和最终的临床调查。